A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

被引：0

作者：

O'Donnell, Elizabeth K. ^{[1
,2
]}

Laubach, Jacob P. ^{[2
,3
]}

Yee, Andrew J. ^{[1
,2
,4
]}

Huff, Carol A. ^{[5
]}

Basile, Frank G. ^{[6
]}

Wade, Philip M., Jr. ^{[6
]}

Paba-Prada, Claudia E. ^{[2
,3
]}

Ghobrial, Irene M. ^{[2
,3
]}

Schlossman, Robert L. ^{[2
,3
]}

Couture, Nicole R. ^{[1
]}

Doherty, Lauren ^{[1
]}

Lyons, Hannah ^{[4
]}

English, Caroline ^{[5
]}

Munshi, Nikhil C. ^{[2
,3
]}

Anderson, Kenneth C. ^{[2
,3
]}

Richardson, Paul C. ^{[2
,3
]}

Raje, Noopur S. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[2] Harvard Univ, Sch Med, Boston, MA USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Massachusetts Gen North Shore Canc Ctr, Danvers, MA USA

[5] Johns Hopkins Univ, Baltimore, MD USA

[6] Cape Cod Healthcare, Hyannis, MA USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
O'Donnell, Elizabeth
Laubach, Jacob P.
Yee, Andrew J.
Huff, Carol Ann
Basile, Frank
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Couture, Nicole
Doherty, Lauren
Lyons, Hannah
English, Caroline
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2014, 124 (21)
[2] Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
O'Donnell, Elizabeth K.
Laubach, Jacob P.
Yee, Andrew J.
Redd, Robert
Huff, Carol Ann
Basile, Frank
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Burke, Jill N.
Harrington, Cynthia C.
Lively, Kathleen J.
Lyons, Hannah
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur S.
BLOOD, 2019, 134
[3] Final Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) in Transplant-Ineligible Multiple Myeloma
O'Donnell, Elizabeth
Laubach, Jacob
Yee, Andrew J.
Chen, Tianqi
Huff, Carol Ann
Basile, Frank G.
Wade, Philip
Paba-Prada, Claudia
Ghobrial, Irene M.
Schlossman, Robert
Burke, Jill
Cynthia, Harrington
Lively, Kathleen
Lyons, Hannah
Munshi, Nikhil
Trippa, Lorenzo
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2017, 130
[4] A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
O'Donnell, Elizabeth K.
Laubach, Jacob P.
Yee, Andrew J.
Chen, Tianqi
Huff, Carol Ann
Basile, Frank G.
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Burke, Jill N.
Harrington, Cynthia C.
Lively, Kathleen J.
Lyons, Hannah F.
Munshi, Nikhil C.
Anderson, Kenneth C.
Trippa, Lorenzo
Richardson, Paul G.
Raje, Noopur S.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 222 - 230
[5] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon, Thierry
Venner, Christopher P.
Bahlis, Nizar J.
Offner, Fritz
White, Darrell J.
Karlin, Lionel
Benboubker, Lotfi
Rigaudeau, Sophie
Rodon, Philippe
Voog, Eric
Yoon, Sung-Soo
Suzuki, Kenshi
Shibayama, Hirohiko
Zhang, Xiaoquan
Twumasi-Ankrah, Philip
Yung, Godwin
Rifkin, Robert M.
Moreau, Philippe
Lonial, Sagar
Kumar, Shaji K.
Richardson, Paul G.
Rajkumar, S. Vincent
BLOOD, 2021, 137 (26) : 3616 - 3628
[6] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O'Donnell, Elizabeth K.
Suman, Vera Jean
Geyer, Susan M.
Nadeem, Omar
Dinner, Shira
Yee, Andrew J.
Laubach, Jacob P.
Mo, Clifton C.
Tuchman, Sascha A.
Donadio, Kristen
Sinclair, Sarah
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[7] Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Usmani, Saad Z.
Facon, Thierry
Hungria, Vania
Bahlis, Nizar J.
Venner, Christopher P.
Braunstein, Marc
Pour, Ludek
Marti, Josep
Basu, Supratik
Cohen, Yael C.
Matsumoto, Morio
Suzuki, Kenshi
Hulin, Cyrille
Grosicki, Sebastian
Legiec, Wojciech
Beksac, Meral
Maiolino, Angelo
Liu, Weiping
Wang, Jianping
Krevvata, Maria
Lopez-Masi, Lorena
Carey, Jodi
Rowe, Melissa
Carson, Robin
Zweegman, Sonja
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S288 - S289
[8] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Takamatsu, Hiroyuki
Iida, Shinsuke
Shibayama, Hirohiko
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701
[9] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Hiroyuki Takamatsu
Shinsuke Iida
Hirohiko Shibayama
Kazuhiro Shibayama
Hiroshi Yamazaki
Kenshi Suzuki
International Journal of Hematology, 2020, 111 : 692 - 701
[10] Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kostopoulos, Ioannis V.
Syrigou, Rodanthi-Eleni
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Tsitsilonis, Ourania E.
Kastritis, Efstathios
Dimopoulos, Meletios A.
HAEMATOLOGICA, 2024, 109 (08) : 2594 - 2605

← 1 2 3 4 5 →